MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 255 filers reported holding MYRIAD GENETICS INC in Q2 2016. The put-call ratio across all filers is 3.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $996,000 | -23.9% | 35,866 | -9.0% | 0.03% | -23.8% |
| Q1 2019 | $1,308,000 | +12.3% | 39,396 | -1.7% | 0.04% | +2.4% |
| Q4 2018 | $1,165,000 | -36.3% | 40,067 | +0.7% | 0.04% | -24.1% |
| Q3 2018 | $1,830,000 | +12.5% | 39,791 | -8.6% | 0.05% | +12.5% |
| Q2 2018 | $1,626,000 | +23.6% | 43,516 | -2.3% | 0.05% | +6.7% |
| Q1 2018 | $1,316,000 | -68.2% | 44,541 | -63.1% | 0.04% | -68.1% |
| Q4 2017 | $4,140,000 | +24.8% | 120,546 | +31.4% | 0.14% | +24.8% |
| Q3 2017 | $3,318,000 | -15.9% | 91,715 | -39.9% | 0.11% | -23.6% |
| Q2 2017 | $3,946,000 | +34.6% | 152,715 | 0.0% | 0.15% | +38.3% |
| Q1 2017 | $2,932,000 | +46.9% | 152,715 | +27.6% | 0.11% | +57.4% |
| Q4 2016 | $1,996,000 | -19.0% | 119,715 | 0.0% | 0.07% | +54.5% |
| Q3 2016 | $2,464,000 | -4.9% | 119,715 | +41.3% | 0.04% | -4.3% |
| Q2 2016 | $2,592,000 | – | 84,715 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,750,000 | $75,900,000 | 2.61% |
| PFM Health Sciences, LP | 2,025,681 | $55,909,000 | 1.90% |
| Tieton Capital Management, LLC | 118,456 | $3,269,000 | 1.83% |
| Altium Capital Management LP | 190,000 | $5,244,000 | 1.45% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,846,490 | $50,963,000 | 1.03% |
| EARNEST PARTNERS LLC | 6,316,365 | $174,332,000 | 1.01% |
| Glenview Capital Management | 1,679,747 | $46,361,000 | 0.99% |
| Zebra Capital Management LLC | 14,209 | $392,000 | 0.63% |
| AIMZ Investment Advisors, LLC | 44,185 | $1,220,000 | 0.48% |
| Phocas Financial Corp. | 132,101 | $3,646,000 | 0.46% |